Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 19, Issue SUPPL. 2, 2008, Pages

  Harousseau, J L ^a,c   Dreyling, M ^b,c  

^a HÔTEL DIEU   (France)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; BONE METASTASIS; CANCER INCIDENCE; CANCER REGRESSION; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; MONOTHERAPY; MULTIPLE MYELOMA; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; RISK ASSESSMENT; TREATMENT PLANNING; TREATMENT RESPONSE; INCIDENCE; PATHOLOGY; RECURRENT DISEASE;

FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MULTIPLE MYELOMA; NEOPLASM STAGING; RECURRENCE;

EID: 45149128933     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn088     Document Type: Article

References (14)

1. Alexanian R, Dimopoulos D. The treatment of multiple myeloma. N Engl J Med 1994; 330: 484-489.
2. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
3. Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
4. Mead GP, Carr-Smith HD, Drayson MT et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126: 348-354.
5. Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006; 108: 3289-3294.
6. Attal M, Harousseau JL. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
7. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
8. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
9. Richardson PG, Sonneveld P, Schuster MW et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) investigators. Bortezomib or highdose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
10. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
11. Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone for newly diagnosed myeloma. Blood 2005; 106: 4050-4053.
12. Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006; 367: 825-831.
13. Facon T, Mary JY, Hulin C et al. Randomized study comparing melphalan prednisone, melphalan prednisone plus thalidomide and intermediate dose melphalan + autologous transplantation in elderly patients: Results of the IFM 99-06 trial. Blood 2005; 104 (Suppl 1): #780, 230 a.
14. Rajkumar V, Blaad E, Vesole D et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.